Therapeutic oligonucleotides continue to grow in their contribution to the pipelines of pharma and biopharma companies. Oligonucleotides are a chemically distinct class from small-molecule or protein therapeutics and present their own unique challenges for characterization and quantification. As a consequence of their highly serial synthesis and use of modified nucleotides, oligonucleotides are uniquely susceptible to fairly high levels of synthetic impurities. This webcast will seek to provide you with a high-resolution mass spectrometry (HRMS) workflow to identify and characterize these impurities.
Quantification of oligonucleotides is complicated by the typical use of ion-pairing reagents. A simple way to overcome this is to use a lower flow that maintains system uptime and increases sensitivity. In addition, this webcast will provide details on the advances of current techniques for microflow LC-MS quantification of oligonucleotides.
Key Learning Objectives:
Who Should Attend:
Scientists or lab directors already supporting oligonucleotide therapeutic development or those considering doing so
For questions, please contact Martha Devia: email@example.com_1597162100162